Effect of interferon therapy on bone marrow morphology in chronic myeloid leukemia: A cytochemical and immunohistochemical study of trephine biopsies

Journal of Interferon and Cytokine Research

Volumn 16, Issue 3, 1996, Pages 217-224

  Thiele, Juergen ^a   Zirbes, Thomas Karl ^a   Kvasnicka, Hans Michael ^a   Lorenzen, Johann ^a   Niederle, Norbert ^b   Leder, Lutz Dietrich ^c   Fischer, Robert ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADULT; ARTICLE; CELL DEATH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; FEMALE; GRANULOPOIESIS; HUMAN; HUMAN TISSUE; MACROPHAGE ACTIVATION; MALE; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0030012316     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.217     Document Type: Article

References (70)

1. MORRA, E., LAZZARINO, M., ALIMENA, G., LIBERATI, A.M., GRIGNANI, F., MANDELLI, F., and BERNASCONI, C. (1992). The role of interferon in the treatment of chronic myelogenous leukemia: results and prospects. Leuk Lymph 6, 305-315.
2. KLOKE, O., WANDL, U., OPALKA, B., MORITZ, T., NAGELHIEMKE, M., FRANZ, T., HIRCHE, H., SEEBER, S., and NIEDERLE, N. (1992). A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. Eur. J. Haematol. 58, 93-98.
3. KANTARJIAN, H.M., and TALPAZ, M. (1993). Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M.D. Anderson Cancer Center. Leuk. Lymph. 11, 169-174.
4. NIEDERLE, N., KLOKE, O., WANDL, U.B., BECHER, R., MORITZ, T., and OPALKA, B. (1993). Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Leuk. Lymph. 9, 111-119.
5. OZER, H., GEORGE, S.L., SCHIFFER, C.A., RAO, K., RAO, P.N., WURSTER-HILL, D.H., ARTHUR, D.D., POWELL, B., GOTTLIEB, A., PETERSON, B.A., RAI, K., TESTA, J.R,. LEBEAU, M., TANTRAVAHI, R., and BLOOMFIELD, C.D. (1993). Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B Study 8583. Blood 82, 2975-2984.
6. ITALIAN COOPERATIVE STUDY GROUP ON CHRONIC MYELOID LEUKEMIA (1994). Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330, 820-825.
7. HEHLMANN, R., HEIMPEL, H., HASFORD, J., KOLB, H.J., PRALLE, H., HOSSFELD, D.K., QUEISSER, W., LOEFFLER, H., HOCHHAUS, A., HEINZE, B., GEORGII, A., et al. (1994). Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84, 4064-4077.
8. AULITZKY, W.E., PESCHEL, C., SCHNELLER, F., and HUBER, C. (1995). Biotherapy of chronic myelogenous leukemia. Ann. Hematol. 70, 113-120.
9. STELLA, C.C., and CAZZOLA, M. (1988). Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. Haematologica (Pavia) 73, 225-237.
10. MURPHY, M. PERUSSIA, B., and TRINCHIERI, G. (1988). Effects of recombinant tumor necrosis factor, lymphotoxin, and immune interferon on proliferation and differentiation of enriched hematopoietic precursors cells. Exp. Hematol. 16, 131-138.
11. PELUS, L.M., OTTMANN, O.G., and NOCKA, K.H. (1988). Synergistic inhibition of human marrow granulocyte-macrophage progenitors cells by prostaglandin E and recombinant interferon-α, -β, and gamma and an effect mediated by tumor necrosis factor. J. Immunol. 140, 479-484.
12. GALVANI, D.W., and CAWLEY, J.C. (1989). Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Br. J. Haematol. 73, 475-479.
13. SHAN, B., VAZQUEZ, E., and LEWIS, J.A. (1990). Interferon selectively inhibits the expression of mitochondrial genes: a novel pathway for interferon-mediated responses. EMBO J. 9, 4307-4314.
14. GALVANI, D.W., and CAWLEY, J.C. (1990). The effects of interferon on human long-term bone marrow culture. Leuk. Res. 14, 525-531.
15. OSTERHOLZ, J., DOWDING, C., GUO, A.P., SICZKOWSKI, M., and GOLDMAN, J.M. (1991). Interferon-α alters the distribution of CFU-GM between the adherent and nonadherent compartments in long-term cultures of chronic myeloid leukemia marrow. Exp. Hematol. 19, 326-331.
16. DOWDING, C., GOU, A.P., OSTERHOLZ, J., SICZKOWSKI, M., GOLDMAN, J., and GORDON, M. (1991). Interferon-α overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78, 499-505.
17. DEISSEROTH, A.B., ZAHNG, W., CHA, Y., YUAN, T., CHEN, H., SIMS, S., WEDRYCHOWSKI, A., GAO, P.-Q., HUSTON, L., FILACCIO, M., CLAXTON, D., KORNBLAU, S., JOHNSON, E., HOWARD, O.M.Z., ANDERSSON, B., DEL GIGLIO, A., GRESSOT, L., KANTARJIAN, H., TALPAZ, M., KHOURI, I., CHAMPLIN, R., ANDREEFF, M., GAOZZA, E., SEONG, D., SUH, S.-P., ELLERSON, D., HU, G., and CHOU, M. (1992). New directions in the biology and therapy of chronic myeloid leukemia. Leuk. Lymph. 6, 89-95.
18. DOWDING, C., GORDON, M., GUO, A.P., MAISON, D., OSTERHOLZ, J., SICZKOWSKI, M., and GOLDMAN, J. (1993). Potential mechanisms of action of interferon-alpha in CML. Leuk. Lymph. 11, 185-191.
19. THIELE, J., KVASNICKA, H.M., NIEDERLE, N., ZIRBES, T.K., SCHMIDT, M., DAMMASCH, J., MEUTER, B.R., LEDER, L.-D., KLOKE, O., DIEHL, V., and FISCHER, R. (1995). The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML - a comparative morphometric study on sequential trephine biopsies. Ann. Hematol. 70, 121-128.
20. 4 isolectin. Proc. Natl. Acad. Sci. USA 79, 166-170.
21. 4: effect on cytotoxicity and protein secretion. J. Cell. Physiol. 147, 265-273.
22. 4-binding-activity. J. Leukoc. Biol. 45, 452-457.
23. HALL, P.A., LEVISON, D.A., WOODS, A.L., YU, C.C.W., KELLOCK, D.B., WATKINS, J.A., BARNES, D.M., GILLET, C.E., CAMPLEJOHN, R., DOVER, R., WASEEM, N.H., and LANE, D.P. (1990). Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J. Pathol. 162, 285-294.
24. MCCORMICK, D., and HALL, P.A. (1992). The complexities of proliferating cell nuclear antigen. Histopathology 21, 591-594.
25. ANSARI, B., COATES, P.J., GREENSTEIN, B.D., and HALL, P.A. (1993). In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J. Pathol. 170, 1-8.
26. FEHSEL, K., KRÖNCKE, K.D., KOLB, H., and KOLB-BACHOFEN, V. (1994). In situ nick-translation detects focal apoptosis in thymuses of glucocorticoid- and lipopolysaccharide-treated mice. J. Histochem. Cytochem. 42, 613-619.
27. COATES, P.J., SAVE, V., ANSARI, B., and HALL, P.A. (1995). Demonstration of DNA damage/repair in individual cells using in situ end labelling: association of p53 with sites of DNA damage. J. Pathol. 176, 19-26.
28. THIELE, J., KVASNICKA, H.M., TITIUS, B.R., PARPERT, U., NEBEL, R., ZANKOVICH, R., DIENEMANN, D., STEIN, H., DIEHL, V., and FISCHER, R. (1993). Histological features of prognostic significance in CML - an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Ann. Hematol. 66, 291-302.
29. THIELE, J., HOEFER, M., KVASNICKA, H.M., BERTSCH, H.P., ZANKOVICH, R., and FISCHER, R. (1993). Erythropoiesis in CML - immunomorphometric quantification, PCNA-reactivity, and influence on survival. Hematol. Pathol. 7, 239-249.
30. BURKHARDT, R., BARTL, R., JAEGER, K., FRISCH, B., KETTNER, G., MAHL, G., and SUND, M. (1984). Chronic myeloproliferative disorders (CMPD). Pathol. Res. Pract. 179, 131-186.
31. BURKHARDT, R. (1988). Bone marrow in megakaryocytic disorders. Hematol. Oncol. Clin. North Am. 2, 695-733.
32. GEORGII, A., VYKOUPIL, K.F., BUHR, T., CHORITZ, H., DÖHLER, U., KALOUTSI, V., and WERNER, M. (1990). Chronic myeloproliferative disorders in bone marrow biopsies. Pathol. Res. Pract. 186, 3-27.
33. THIELE, J., and FISCHER, R. (1991). Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. Virchows Arch. [A] 418, 81-97.
34. OPALKA, B., WANDL, U.B., BECHER, R., KLOKE, O., NAGEL-HIEMKE, M., MORITZ, T., BEER, U., SEEBER, S., and NIEDERLE, R. (1991). Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon α-2b alone or in combination with interferon gamma. Blood 78, 2188-2193.
35. LAZZARINO, M., MORRA, E., CASTELLO, A., INVERARDI, D., COCI, A., PAGNUCCO, G., MAGRINI, U., ZEI, G., and BERNASCONI, C. (1986). Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance. Br. J. Haematol. 64, 227-240.
36. BUHR, T., CHORITZ, H., and GEORGII, A. (1992). The impact of megakaryocyte proliferation for the evolution of myelofibrosis. Histologic follow-up study in 186 patients with chronic myeloid leukemia. Virchows Arch. [A] 420, 473-478.
37. CASTRO-MALASPINA, H. (1984). Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. In: Myelofibrosis and the Biology of Connective Tissue. P. Berk, H. Castro-Malaspina, and L. Wasserman (eds.) New York: Liss, pp. 427-454.
38. MACCARTHY, D.M. (1985). Fibrosis of the bone marrow: content and causes. Br. J. Haematol. 59, 1-7.
39. YONEKURA, S., NAGAO, T., and ARIMORI, S. (1985). Increased growth and collagen synthesis of bone marrow fibroblasts from patients with chronic myelocytic leukaemia. Br. J. Haematol. 61, 93-99.
40. KIMURA, A., KATOH, O., and KURAMOTO, A. (1988). Effects of platelet-derived growth factor, epidermal growth factor and transforming growth factor-β on growth of human marrow fibroblasts. Br. J. Haematol. 69, 9-12.
41. KATOH, O., KIMURA, A., ITOH, T., and KURAMOTO, A. (1990). Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am. J. Haematol. 35, 145-150.
42. PACE, J.L., RUSSELL, S.W., TORRES, B.A., JOHNSON, H.M., and GRAY, P.W. (1983). Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J. Immunol. 130, 2011-2013.
43. VARESIO, L., BLASI, E., THURMAN, G.B., TALMADGE, J.E., WILTROUT, R.H., and HERBERMANN, R.B. (1984). Potent activation of mouse macrophages by recombinant interferon-gamma. Cancer Res. 44, 4465-4469.
44. HERRIOTT, J.J., and LEU, R.W. (1987). Activation of mouse macrophages for migration inhibition and for tumor cytotoxicity is mediated by interferon-gamma priming and triggering by various agents. J. Interferon Res. 7, 165-171.
45. MADDOX, D.E., GOLDSTEIN, I.J., and LOBUGLIO, A.F. (1982). Griffonia simplicifolia I Iectin mediates macrophage-induced cytotoxicity against Ehrlich ascites tumor. Cell. Immunol. 71, 202-207.
46. IRIMURA, T., NORTH, S.M., and NICOLSON, G.L. (1987). Glycoprotein profiles of macrophages at different stages of activation as revealed by lectin binding after electrophoretic separation. Eur. J. Immunol. 17, 73-78.
47. 4, recognize the same tumor-associated structure (TAS). J. Immunol. 138, 1999-2007.
48. WARFEL, A.H., and ZUCKER-FRANKLIN, D. (1992). Specific ligation of surface α-D-galactosyl epitopes markedly affects the quantity of four major proteins secreted by macrophages. J. Leukoc. Biol. 52, 80-84.
49. ADAMS, D.O., and HAMILTON, T.A. (1984). The cell biology of macrophage activation. Annu. Rev. Immunol. 2, 283-318.
50. SMITH, C.A., FARRAH, T., and GOODWIN, R.G. (1994). The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959-962.
51. SOKAL, J.E., SHEERIN, K.A. (1986). Decreased stainable marrow iron in chronic granulocytic leukemia. Am. J. Med. 81, 395-399.
52. ARENDS, M.J., and WYLLIE, A.H. (1991). Apoptosis: mechanism and roles in pathology. Int. Rev. Exp. Pathol. 32, 223-254.
53. ALLEN, P.D., BUSTIN, S.A., and NEWLAND, A.C. (1993). The role of apoptosis (programmed cell death) in haemopoiesis and the immune system. Blood Rev. 7, 63-73.
54. WILLIAMS, G.T. (1994). Apoptosis in the immune system. J. Pathol. 173, 1-4.
55. KERR, J.F.R., WINTERFORD, C.M., and HARMON, B.V. (1994). Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013-2026.
56. KOURY, M.J. (1992). Programmed cell death (apoptosis) in hematopoiesis. Exp. Hematol. 20, 391-394.
57. PAYNE, C.M., BERNSTEIN, C., and BERNSTEIN, H. (1995). Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal-transduction pathways. Leuk. Lymph. 19, 43-93.
58. SAVILL, J., FADOK, V., HENSON, P., and HASLETT, C. (1993). Phagocyte recognition of cells undergoing apoptosis. Immunol. Today 14, 131-136.
59. LOTEM, J., and SACHS, L. (1992). Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80, 1750-1757.
60. LI, X., GONG, J., FELDMAN, E., SEITER, K., TRAGNOS, F., and DARZYNKKIEWICZ, Z. (1994). Apoptotic cell death during treatment of leukemias. Leuk. Lymph. 13, 65-70.
61. COLOTTA, F., RE, F., POLENTARUTTI, N., SOZZANI, S., and MANTOVANI, A. (1992). Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80, 2012-2020.
62. HOFFMAN, B., and LIEBERMANN, D.A. (1994). Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators. Oncogene 9, 1807-1812.
63. SELVAKUMARAN, M., LIN, H.K., TJIN THAM SJIN, R., REED, J.C., LIEBERMANN, D.A., and HOFFMAN, B. (1994). The novel primary response gene MyD 118 and the protooncogenes myb, myc, and bcl-2 modulate transforming growth factor β1 -induced apoptosis of myeloid leukemia cells. Mol. Cell. Biol. 14, 2352-2360.
64. MCWHIRTER, J.R., and WANG, J.Y.J. (1991). Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol. Cell. Biol. 11, 1553-1565.
65. MARTIN, S.J., LENNON, S.V., BONHAM, A.M., and COTTER, T.G. (1990). Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA and protein synthesis. J. Immunol. 145, 1859-1867.
66. MCGAHON, A., BISSONNETTE, R., SCHMITT, M., COTTER, K.M., GREEN, D.R., and COTTER, T.C. (1994). Bcr-abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83, 1179-1187.
67. COTTER, T.C. (1995). Bcr-abl: an anti-apoptosis gene in chronic myelogenous leukemia. Leuk. Lymph. 18, 231-236.
68. DOERMER, P., LAU, B., and WILMANNS, W. (1980). Kinetics of bone marrow cell production in human acute and chronic leukemias. Leuk. Res. 4, 231-237.
69. STRIFE, A., and CLARKSON, B. (1988). Biology of chronic myelogenous leukaemia: is discordant maturation the primary defect? Semin. Hematol. 25, 1-19.
70. GORDON, M.Y. (1993). Regulation of growth in chronic myeloid leukemia. Leuk. Lymph. 11, 75-79.